Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: Results of a prospective study in a clinical setting

European Urology

Volumn 60, Issue 2, 2011, Pages 214-222

  Guazzoni, Giorgio ^a   Nava, Luciano ^a   Lazzeri, Massimo ^a   Scattoni, Vincenzo ^a   Lughezzani, Giovanni ^a   MacCagnano, Carmen ^a   Dorigatti, Fernanda ^b   Ceriotti, Ferruccio ^b   Pontillo, Marina ^b   Bini, Vittorio ^c   Freschi, Massimo ^a   Montorsi, Francesco ^a   Rigatti, Patrizio ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Diagnostic accuracy; proPSA; Prostate biopsy; Prostate cancer; Prostate specific antigen; PSA; PSA isoforms

Indexed keywords

P2 PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TUMOR VOLUME;

ACADEMIC MEDICAL CENTERS; AGED; BIOPSY; HEALTH STATUS INDICATORS; HUMANS; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 79959554692     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.03.052     Document Type: Article

References (18)

1. F.H. Schroder, and M.J. Roobol Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer Curr Opin Urol 19 2009 227 231
2. E.A. Heijnsdijk, A. der Kinderen, and E.M. Wever Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer Br J Cancer 101 2009 1833 1838
3. I.M. Thompson, D.K. Pauler, and P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter N Engl J Med 350 2004 2239 2246
4. A.W. Roddam, M.J. Duffy, and F.C. Hamdy Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis Eur Urol 48 2005 386 399
5. C. Stephan, G. Stroebel, and M. Heinau The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in the range of < 4 ng/mL Cancer 104 2005 993 1003 (Pubitemid 41170227)
6. F.K.-H. Chun, J.I. Epstein, and V. Ficarra Optimizing performance and interpretation of prostate biopsy: a critical analysis of the literature Eur Urol 58 2010 851 864
7. S.D. Mikolajczyk, L.S. Millar, and T.J. Wang A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue Cancer Res 60 2000 756 759 (Pubitemid 30094578)
8. W.J. Catalona, G. Bartsch, and H.G. Rittenhouse Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml J Urol 170 2003 2181 2185 (Pubitemid 37413952)
9. L.J. Sokoll, Y. Wang, and Z. Feng [-2]Proenzyme prostate specific antigen for prostate cancer detection: a National Cancer Intitute early detection research network validation study J Urol 180 2008 539 543
10. C. Stephan, A.M. Kahrs, and H. Cammann A [-2]proPSA-based artificial neural network significantly improves differentiation between protate cancer and benign prostatic diseases Prostate 69 2009 198 207
11. L.J. Sokoll, M.G. Sanda, and Z. Feng A prospective, multicenter, National Cancer Institute Early Detection Research Network Study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness Cancer Epidemiol Biomarkers Prev 19 2010 1193 1200
12. B.V. Le, C.R. Griffin, and S. Loeb [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study J Urol 183 2010 1355 1359
13. F.H. Jansen, R.H.N. Van Schaik, and J. Kurstjens Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection Eur Urol 57 2010 921 927
14. A. Semjonow, T. Köpke, and E. Eltze Pre-analytical in-vitro stability of [-2]proPSA in blood and serum Clin Biochem 47 2010 926 928
15. V. Scattoni, M. Raber, and F. Abdollah Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy Eur Urol 57 2010 1 8
16. J.I. Epstein, W.C. Allsbrook Jr., and M.B. Amin The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228 1242 (Pubitemid 41232997)
17. D.W. Hosmer, and S. Lemeshow Applied logistic regression 2000 Wiley New York, NY
18. E.R. DeLong, D.M. DeLong, and D.L. Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach Biometrics 44 1988 837 845